Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 14/20 | 0.68 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.64 |
| ▸ | PTGES | O14684 | 1/20 | 0.64 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.64 |
| ▸ | CNR1 | P21554 | 1/20 | 0.62 |
| ▸ | CNR2 | P34972 | 1/20 | 0.62 |
| ▸ | APLNR | P35414 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7365048 | 0.88 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL20594841 | 0.85 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL1888996 | 0.85 | TAS2R14 (0.81) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL22501451 | 0.85 | TAS2R14 (0.68) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL2445958 | 0.84 | TAS2R14 (0.82) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL28729777 | 0.84 | TAS2R14 (0.80) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL21773447 | 0.84 | BMP1 (0.59) | TAS2R14CXCR3PTGESTAS2R8APLNR | |
| SCHEMBL24724011 | 0.83 | TAS2R14 (0.62) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL31149240 | 0.83 | TAS2R14 (0.55) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL24724004 | 0.81 | TAS2R14 (0.80) | TAS2R14CXCR3PTGESTAS2R8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695242-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | Meta Pharmaceuticals (HK) Limited (HK) | 2026-02-18 | — | — | EP | disclosed |
| WO-2024212907-A1 | NOVEL SUBSTITUTED PYRROLE COMPOUNDS, COMPOSITIONS COMPRISING THE SUBSTITUTED PYRROLE COMPOUND, AND METHODS OF USE THEREOF | META PHARMACEUTICALS (HK) LIMITED (CN) | 2024-10-17 | — | — | WO | disclosed |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS PHARMA AG (CH) | 2023-06-15 | — | — | US | disclosed |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | NOVARTIS PHARMA AG (CH) | 2023-06-15 | — | — | US | disclosed |
| EP-4153585-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | Chinook Therapeutics Canada, Inc. (CA) | 2023-03-29 | — | — | EP | disclosed |
| WO-2021234547-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | CHINOOK THERAPEUTICS CANADA, INC. (CA) | 2021-11-25 | — | — | WO | disclosed |
| US-10683308-B2 | Rapamycin analogs and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-20190031683-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2019-01-31 | — | — | US | disclosed |
| WO-2017044720-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2013-12-26 | — | — | US | disclosed |
| US-8569345-B2 | Compounds and compositions as LXR modulators | MOLTENI VALENTINA (US) | 2013-10-29 | — | — | US | disclosed |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2012-08-23 | — | — | US | disclosed |
| US-8158662-B2 | Compounds and compositions as LXR modulators | HAMILTON (BM) | 2012-04-17 | — | — | US | disclosed |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | IRM LLC (BM) | 2009-12-31 | — | — | US | disclosed |
| EP-1713799-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM, LLC (BM) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077124-A2 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | IRM LLC (BM) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345220-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | TAS2R14 4411/4885CXCR3 261/4885PTGES 621/4885 |
| US-20190031683-A1 | RAPAMYCIN ANALOGS AND USES THEREOF | RICTOR, MTOR, RPTOR | TAS2R14 4466/4885CXCR3 1756/4885PTGES 3537/4885 |
| US-10683308-B2 | Rapamycin analogs and uses thereof | RICTOR, MTOR, RPTOR | TAS2R14 4466/4885CXCR3 1756/4885PTGES 3537/4885 |
| US-20230183228-A1 | SUBSTITUTED PYRAZOLYL COMPOUNDS AND METHODS OF USE THEREOF | LDHA, LDHB, XDH | TAS2R14 3827/4885CXCR3 3867/4885PTGES 1795/4885 |
| US-20090325981-A1 | Compounds and compositions as lxr modulators | NR1H2, NR1H3, NR1H4 | TAS2R14 4411/4885CXCR3 261/4885PTGES 621/4885 |
| US-20120214812-A1 | COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS | NR1H2, NR1H3, NR1H4 | TAS2R14 4411/4885CXCR3 261/4885PTGES 621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.